Walgreens Concludes Public Trading Era with Sycamore Acquisition

The corporate structure of Walgreens has undergone a fundamental transformation with the completion of its acquisition by private equity firm Sycamore Partners. The deal, which was initially announced in March 2025, values the pharmacy giant at approximately $23.7 billion and has resulted in the immediate delisting of Walgreens Boots Alliance (WBA) stock from the Nasdaq exchange. This move ends the company’s nearly century-long tenure as a publicly traded entity, which began in 1927.

Concurrent with the change in ownership, a significant leadership overhaul is underway. Mike Motz has been appointed Chief Executive Officer, succeeding Tim Wentworth. Motz brings extensive retail experience to the role, having previously served as CEO of Staples US Retail—another company within Sycamore’s portfolio—and as president of Canadian pharmacy chain Shoppers Drug Mart. Wentworth will remain with the organization in a directorial capacity on the board. Furthermore, John Lederer, a former Walgreens director and current senior advisor at Sycamore, has been named Executive Chairman.

Strategic Overhaul and Corporate Separation

The decision to transition to private ownership follows a period of significant challenges for the 125-year-old company, driven by shifting consumer behaviors and intensifying competition within the healthcare sector. Operating away from the scrutiny of public markets is expected to provide the flexibility required to execute long-term strategic plans without the pressure of quarterly earnings reports.

Newly appointed CEO Mike Motz emphasized this advantage, stating, “As a private company, we can renew our focus on our core pharmacy and retail businesses, our stores, and the customer experience.”

Should investors sell immediately? Or is it worth buying Walgreens?

The acquisition triggers a major corporate restructuring. The various components of Walgreens Boots Alliance will be separated to operate as independent entities. This includes The Boots Group, Shields Health Solutions, CareCentrix, and VillageMD. The breakup is designed to allow each distinct business unit to sharpen its strategy and better address the specific demands of its respective market.

A New Chapter with Private Equity Backing

The future direction of Walgreens will now be determined by Sycamore Partners, which executed the takeover in collaboration with Stefano Pessina and his family, who reinvested their entire stake. The focus is squarely on revitalizing the core US pharmacy and retail operations.

Stefan Kaluzny, Managing Director at Sycamore, expressed confidence that private ownership will enable Walgreens to “deliver substantial value to customers with determination, focus, and agility.”

The company’s final quarterly report as a public entity, for the period ending May 31, 2025, highlighted both strengths and challenges. It showed a 7 percent year-over-year increase in revenue to $39.0 billion, but also revealed a 2.4 percent decline in comparable retail sales. Addressing these weaknesses in the brick-and-mortar store performance will be a primary task for the new leadership team as they begin this new chapter away from the public spotlight.